Literature DB >> 1980125

Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?

R P Tang1, B Kacinski, P Validire, F Beuvon, X Sastre, P Benoit, A dela Rochefordière, V Mosseri, P Pouillart, S Scholl.   

Abstract

One hundred six primary breast cancer samples were analysed for c-erbB2, int-2, and c-myc gene amplification. Surgically confirmed nodal involvement was observed in 42%. Level of gene amplification was studied by Southern and/or slot blot techniques. Amplified c-erbB2 gene sequences were present in 21.5% of all samples. Int-2 was amplified in 13.1% and c-myc was amplified in 10.3%. In a non-parametric test (Kruskal-Wallis) a strong negative association was found between high levels of c-erbB2 amplification and absence of estrogen receptor (ER) (P = .0009) or progesterone receptor (PR) (P = .011) expression. No correlations were found between all or high levels of amplification of each oncogene separately or combined with T, N, grade, multifocality of tumor, or associated carcinoma in situ. There was a trend approaching statistical significance for patients with c-erbB2 amplifications to have positive lymph nodes at surgery (P = 0.09). A somewhat surprising finding however was a very strong association between oncogene amplification and dense lymphocyte infiltration of the tumor (P = .05). This correlation is even stronger when only high levels of amplification are considered, either for each oncogene separately (P = .0048) or in combination (P = .0007). We propose that malignant cell cytokine production may help explain this observation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980125     DOI: 10.1002/jcb.240440307

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  15 in total

1.  Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study.

Authors:  S M Scholl; R Lidereau; A de la Rochefordière; C C Le-Nir; V Mosseri; C Noguès; P Pouillart; F R Stanley
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Hyaluronan inhibits postchemotherapy tumor regrowth in a colon carcinoma xenograft model.

Authors:  Barbara M Mueller; Ingrid U Schraufstatter; Valentina Goncharova; Tatiana Povaliy; Richard DiScipio; Sophia K Khaldoyanidi
Journal:  Mol Cancer Ther       Date:  2010-09-10       Impact factor: 6.261

3.  Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer.

Authors:  Chonglin Tian; Yongsheng Wang; Xianrang Song
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

Review 4.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 5.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

Review 6.  A Molecular View of Pathological Microcalcification in Breast Cancer.

Authors:  Tanu Sharma; James A Radosevich; Geeta Pachori; Chandi C Mandal
Journal:  J Mammary Gland Biol Neoplasia       Date:  2016-01-15       Impact factor: 2.673

Review 7.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

Review 8.  Chromosome 11q13 markers and D-type cyclins in breast cancer.

Authors:  G Peters; V Fantl; R Smith; S Brookes; C Dickson
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.

Authors:  S M Scholl; C H Bascou; V Mosseri; R Olivares; H Magdelenat; T Dorval; T Palangié; P Validire; P Pouillart; E R Stanley
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.